A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy

A pharmacokinetic (PK) model was developed for nusinersen, an antisense oligonucleotide (ASO) that is the first approved treatment for spinal muscular atrophy (SMA). The model was built with data from 92 nonhuman primates (NHPs) following intrathecal doses (0.3–7 mg) and characterized the PK in cere...

Descripción completa

Detalles Bibliográficos
Autores principales: Biliouris, Konstantinos, Gaitonde, Puneet, Yin, Wei, Norris, Daniel A., Wang, Yanfeng, Henry, Scott, Fey, Robert, Nestorov, Ivan, Schmidt, Stephan, Rogge, Mark, Lesko, Lawrence J., Trame, Mirjam N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157691/
https://www.ncbi.nlm.nih.gov/pubmed/30043511
http://dx.doi.org/10.1002/psp4.12323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157691/
https://www.ncbi.nlm.nih.gov/pubmed/30043511
http://dx.doi.org/10.1002/psp4.12323

Ejemplares similares